Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE44.6900
- TODAY'S CHANGE (%)-0.5400 (-1.1939%)
- Bid / Lots44.0000/ 1
- Ask / Lots48.4000/ 1
- Open / Previous Close45.0700 / 45.2300
- Day Range
- 52 Week Range
- Volume617,592
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 5620 | 44.81 |
| 09:34 ET | 3992 | 44.8401 |
| 09:36 ET | 1194 | 45.3 |
| 09:38 ET | 1300 | 45.19 |
| 09:39 ET | 2500 | 45.34 |
| 09:41 ET | 217 | 45.175 |
| 09:43 ET | 697 | 45.155 |
| 09:45 ET | 100 | 45.3 |
| 09:48 ET | 842 | 45.335 |
| 09:50 ET | 200 | 45.52 |
| 09:52 ET | 200 | 45.47 |
| 09:54 ET | 300 | 45.52 |
| 09:56 ET | 2840 | 45.54 |
| 09:57 ET | 1066 | 45.415 |
| 09:59 ET | 200 | 45.3 |
| 10:01 ET | 1310 | 45.415 |
| 10:03 ET | 647 | 45.66 |
| 10:06 ET | 101 | 45.74 |
| 10:08 ET | 700 | 45.86 |
| 10:10 ET | 100 | 45.86 |
| 10:12 ET | 700 | 45.9 |
| 10:15 ET | 900 | 45.96 |
| 10:17 ET | 100 | 45.98 |
| 10:19 ET | 100 | 46 |
| 10:21 ET | 300 | 45.89 |
| 10:24 ET | 100 | 45.98 |
| 10:30 ET | 1100 | 45.88 |
| 10:32 ET | 100 | 45.87 |
| 10:35 ET | 8500 | 45.98 |
| 10:37 ET | 100 | 46.02 |
| 10:39 ET | 200 | 45.96 |
| 10:42 ET | 507 | 45.925 |
| 10:44 ET | 300 | 46.02 |
| 10:46 ET | 400 | 45.83 |
| 10:51 ET | 300 | 45.92 |
| 10:53 ET | 200 | 45.93 |
| 10:55 ET | 100 | 45.93 |
| 10:57 ET | 458 | 45.925 |
| 11:00 ET | 200 | 45.92 |
| 11:06 ET | 100 | 45.93 |
| 11:08 ET | 300 | 45.96 |
| 11:09 ET | 200 | 45.99 |
| 11:13 ET | 440 | 45.93 |
| 11:15 ET | 600 | 45.9 |
| 11:20 ET | 300 | 45.72 |
| 11:26 ET | 100 | 45.77 |
| 11:27 ET | 500 | 45.75 |
| 11:29 ET | 100 | 45.78 |
| 11:33 ET | 300 | 45.71 |
| 11:36 ET | 700 | 45.6 |
| 11:38 ET | 100 | 45.62 |
| 11:40 ET | 200 | 45.565 |
| 11:42 ET | 100 | 45.62 |
| 11:44 ET | 200 | 45.525 |
| 11:45 ET | 400 | 45.585 |
| 11:47 ET | 400 | 45.555 |
| 11:49 ET | 1200 | 45.474 |
| 11:51 ET | 4281 | 45.495 |
| 11:56 ET | 200 | 45.505 |
| 12:00 ET | 100 | 45.57 |
| 12:02 ET | 300 | 45.52 |
| 12:03 ET | 200 | 45.555 |
| 12:07 ET | 500 | 45.46 |
| 12:09 ET | 298 | 45.52 |
| 12:12 ET | 600 | 45.48 |
| 12:14 ET | 420 | 45.57 |
| 12:18 ET | 200 | 45.505 |
| 12:21 ET | 851 | 45.61 |
| 12:23 ET | 100 | 45.62 |
| 12:25 ET | 400 | 45.57 |
| 12:32 ET | 800 | 45.55 |
| 12:34 ET | 3274 | 45.48 |
| 12:36 ET | 100 | 45.47 |
| 12:41 ET | 495 | 45.2 |
| 12:43 ET | 3316 | 45.35 |
| 12:45 ET | 300 | 45.32 |
| 12:48 ET | 315 | 45.305 |
| 12:50 ET | 100 | 45.39 |
| 12:52 ET | 1900 | 45.58 |
| 12:54 ET | 100 | 45.58 |
| 12:56 ET | 200 | 45.585 |
| 12:57 ET | 100 | 45.58 |
| 12:59 ET | 700 | 45.48 |
| 01:01 ET | 100 | 45.56 |
| 01:03 ET | 100 | 45.52 |
| 01:06 ET | 200 | 45.52 |
| 01:10 ET | 428 | 45.52 |
| 01:14 ET | 100 | 45.56 |
| 01:15 ET | 500 | 45.56 |
| 01:17 ET | 100 | 45.59 |
| 01:19 ET | 100 | 45.63 |
| 01:21 ET | 200 | 45.64 |
| 01:28 ET | 1420 | 45.45 |
| 01:32 ET | 100 | 45.46 |
| 01:35 ET | 300 | 45.41 |
| 01:37 ET | 100 | 45.44 |
| 01:39 ET | 500 | 45.37 |
| 01:46 ET | 205 | 45.42 |
| 01:50 ET | 400 | 45.44 |
| 01:51 ET | 1600 | 45.42 |
| 01:53 ET | 1025 | 45.4275 |
| 01:57 ET | 100 | 45.42 |
| 02:00 ET | 1200 | 45.35 |
| 02:06 ET | 100 | 45.365 |
| 02:08 ET | 1095 | 45.3 |
| 02:09 ET | 135 | 45.31 |
| 02:15 ET | 703 | 45.39 |
| 02:18 ET | 100 | 45.45 |
| 02:20 ET | 100 | 45.44 |
| 02:22 ET | 4515 | 45.42 |
| 02:24 ET | 100 | 45.44 |
| 02:27 ET | 5864 | 45.49 |
| 02:29 ET | 200 | 45.46 |
| 02:31 ET | 650 | 45.445 |
| 02:36 ET | 100 | 45.48 |
| 02:38 ET | 910 | 45.48 |
| 02:40 ET | 4695 | 45.355 |
| 02:42 ET | 2766 | 45.28 |
| 02:44 ET | 600 | 45.33 |
| 02:45 ET | 1200 | 45.33 |
| 02:49 ET | 400 | 45.37 |
| 02:56 ET | 2456 | 45.27 |
| 02:58 ET | 1120 | 45.21 |
| 03:00 ET | 100 | 45.21 |
| 03:02 ET | 500 | 45.14 |
| 03:05 ET | 100 | 45.165 |
| 03:07 ET | 24055 | 44.95 |
| 03:09 ET | 4403 | 45.11 |
| 03:12 ET | 1425 | 45.0725 |
| 03:14 ET | 803 | 45.06 |
| 03:16 ET | 350 | 45.07 |
| 03:18 ET | 3900 | 45.065 |
| 03:20 ET | 1525 | 45.055 |
| 03:23 ET | 400 | 44.96 |
| 03:25 ET | 10701 | 44.72 |
| 03:27 ET | 1110 | 44.67 |
| 03:30 ET | 1500 | 44.705 |
| 03:32 ET | 10135 | 44.56 |
| 03:34 ET | 3766 | 44.615 |
| 03:36 ET | 200 | 44.64 |
| 03:38 ET | 800 | 44.53 |
| 03:39 ET | 17150 | 44.495 |
| 03:41 ET | 1100 | 44.47 |
| 03:43 ET | 200 | 44.46 |
| 03:45 ET | 2000 | 44.39 |
| 03:48 ET | 16958 | 44.42 |
| 03:50 ET | 1800 | 44.4 |
| 03:52 ET | 3976 | 44.34 |
| 03:54 ET | 3604 | 44.34 |
| 03:56 ET | 1716 | 44.58 |
| 03:57 ET | 2799 | 44.63 |
| 03:59 ET | 119629 | 44.69 |
Jun 15, 2024
Agios Presents Positive Results from Phase 3 -2-, from 8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
Jun 13, 2024
DJ Agios Pharmaceuticals Price Target Announced at $46.00/Share by JP Morgan, from 5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 6, 2024
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET, from 9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
Jun 4, 2024
DJ Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 11:26AM ET on Tuesday Jun 04, 2024 by Dow Jones
11:26AM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
DJ Agios Pharmaceuticals Shares Rise 16% After Positive Trial Data for Mitapivat, from 10:25AM ET on Monday Jun 03, 2024 by Dow Jones
10:25AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.6B | -7.1x | --- |
Intellia Therapeutics Inc | 2.4B | -4.5x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.1x | --- |
IDEAYA Biosciences Inc | 2.8B | -18.1x | --- |
Structure Therapeutics Inc | 2.5B | -17.2x | --- |
MoonLake Immunotherapeutics | 2.5B | -52.9x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -7.1x |
Price/Sales (TTM) | 87.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
